Systematically Testing the Evidence on Marijuana

The purpose of this study is to see if cannabidiol (CBD) orally dissolving tablets (ODTs) can lessen pain, improve function, and improve patient satisfaction in cases of knee osteoarthritis. CBD comes from the cannabis plant and is non-psychoactive (i.e. does not produce a 'high' or altered mental state) as compared to tetrahydrocannabinol (THC), another compound found in cannabis. Researchers are studying different forms of CBD for potential use in treating pain, inflammation, and illnesses.

First Posted: August 25, 2021

Condition(s): Knee Arthritis

Intervention(s): Cannabidiol (CBD), Placebo

Status: Recruiting

Enrollment (expected or actual): 100

Allocation: Randomized

Sponsor: NYU Langone Health

Principal Investigator:

Completion Date (primary or actual): June 2023

CT.gov Identifier: NCT05020028

A Randomized Clinical Trial that will compare the effects of Cannabidiol and Homotaurine in cognition and mental health in patients with Mild Cognitive Impairment and APOE ε4 carriers. Ninety patients will be recruited and they will be randomly distributed in three groups. The first group will receive treatment with Cannabidiol 5%, the second group will receive treatment with Vivimind and the third group will not receive any treatment. The three groups will be compared by using an extensive neuropsychological examination and biomarkers' results from cerebrospinal fluid and blood

First Posted: August 26, 2021

Condition(s): Mild Cognitive Impairment

Intervention(s): Cannabidiol Oil, Homotaurine

Status: Recruiting

Enrollment (expected or actual): 90

Allocation: Randomized

Sponsor: Aristotle University Of Thessaloniki

Principal Investigator: Magda Tsolaki, Professor of Neurology, Medical School, Aristotle University of Thessaloniki

Completion Date (primary or actual): December 20, 2022

CT.gov Identifier: NCT05022186

There are no FDA approved treatments for use in adults with autism spectrum disorder (ASD), many of whom have distressing anxiety, mood disturbances, sleep problems, and agitation. Some researchers and individuals with ASD have noted that cannabidiol (CBD) is beneficial for those psychiatric problems. This study is to learn more about the effectiveness and safety of CBD in the treatment of psychiatric problems in adults with ASD. The study will last 14 weeks total, during which six weeks participants will receive a pill containing CBD, two weeks where participants will receive no drug/placebo, and six weeks where participants will receive the placebo, an inactive pill. As part of the study, participants will have regular visits and be asked questions about anxiety, challenging behaviors, daily functioning, cognition, and physical symptoms, on standard assessments.

First Posted: August 20, 2021

Condition(s): Autism Spectrum Disorder

Intervention(s): Cannabidiol, Placebo

Status: Not yet recruiting

Enrollment (expected or actual): 40

Allocation: Randomized

Sponsor: Johns Hopkins University

Principal Investigator:

Completion Date (primary or actual): December 2023

CT.gov Identifier: NCT05015439

The purpose of this study is to examine the pharmacokinetics and pharmacodynamics of a hemp-derived oral product containing cannabidiol (CBD) and cannabidiolic acid (CBD-A) at a 1:1 ratio.

First Posted: September 20, 2021

Condition(s): Cannabis

Intervention(s): CBD 1mg/Kg, CBD 2mg/Kg, CBD 4mg/Kg, Placebo CBD

Status: Recruiting

Enrollment (expected or actual): 50

Allocation: Randomized

Sponsor: Johns Hopkins University

Principal Investigator:

Completion Date (primary or actual): December 31, 2022

CT.gov Identifier: NCT05049733

This open-label, 3-period, 3-treatment, randomized study will characterize the pharmacokinetics and safety and tolerability of SP-104 under fasting and fed conditions as compared to the pharmacokinetics of Naltrexone Hydrochloride Tablets, USP, 50 mg in healthy adult subjects.

First Posted: August 12, 2021

Condition(s): Healthy

Intervention(s): SP-104, Naltrexone Hydrochloride 50Mg Oral Tablet

Status: Completed

Enrollment (expected or actual): 18

Allocation: Randomized

Sponsor: Scilex Pharmaceuticals, Inc.

Principal Investigator:

Completion Date (primary or actual): April 24, 2022

CT.gov Identifier: NCT05002946

Double-blind, randomized into two arms (TC and TP): patients get either topical cannabidiol or topical placebo up to three times daily. Inclusion criteria will be chronic joint pain with intent to treat or currently treated with opioids. Exclusion criteria will include current cannabis use, severe medical illness or lacking in capacity to be involved in study. TC and TP will be prescribed for use TID in predefined dosages and quantities.

First Posted: August 12, 2021

Condition(s): Musculoskeletal Joint Pain

Intervention(s): Cannabidiol, Placebo

Status: Withdrawn

Enrollment (expected or actual): 0

Allocation: Randomized

Sponsor: Louisiana State University Health Sciences Center Shreveport

Principal Investigator: James C. Patterson, II, MD. Ph, Clinical Director, Louisiana Addiction Research Center

Completion Date (primary or actual): January 2023

CT.gov Identifier: NCT05002114

The study aims to evaluate the effect of Dorsolateral Prefrontal Cortex (DLPFC) Transcranial Direct Current Stimulation (tDCS) in decreasing distress and cannabis use. 46 participants with Relapse Remitting Multiple Sclerosis (RRMS), Cannabis Use Disorder (CUD) and elevated distress (K10 score of 10-35) will be recruited.

First Posted: August 13, 2021

Condition(s): Cannabis Use Disorder, Multiple Sclerosis

Intervention(s): Transcranial Direct Current Stimulation (tDCS), Sham - Transcranial Direct Current Stimulation (tDCS), Mindfulness

Status: Not yet recruiting

Enrollment (expected or actual): 46

Allocation: Randomized

Sponsor: NYU Langone Health

Principal Investigator:

Completion Date (primary or actual): March 31, 2024

CT.gov Identifier: NCT05005013

This observational study aims to improve our understanding of how legal market cannabis use impacts acute and long-term alcohol use, the microbiota-gut-brain-axis (MGBA), and neurobehavioral alcohol use phenotypes such as impulsivity, impaired cognitive functioning, and craving, among individuals who regularly use both alcohol and cannabis. Over a period of one month, subjects will participate in this three-visit study. Blood samples will be collected to allow for the assessment of inflammatory markers and cannabinoids, a fecal sample will be collected to allow for the analysis of the gut microbiome, and participants will complete cognitive and impulsivity tasks and provide craving ratings during the course of an alcohol self-administration procedure. Subjects will also participate in two 14-day daily diary data collection periods between lab sessions. Daily diary data collection will be used to assess the effects of cannabis use on alcohol use and craving longitudinally.

First Posted: August 10, 2021

Condition(s): Cannabis Use, Alcohol Use, Inflammation

Intervention(s): Alcohol and Cannabis vs. Alcohol only

Status: Recruiting

Enrollment (expected or actual): 61

Allocation:

Sponsor: Colorado State University

Principal Investigator: Hollis Karoly, Assistant Professor

Completion Date (primary or actual): January 31, 2025

CT.gov Identifier: NCT04998006

This is an open label, phase 2 clinical trial to assess the feasibility of a cannabidiol (CBD) dominant medicinal cannabis for the treatment of Long COVID. The primary aim is to assess the feasibility of recruiting and retaining individuals diagnosed with Long COVID into a treatment trial of medicinal cannabis, as well as assessing the safety and tolerability of a dominant medicinal cannabis in this population. The secondary aim is to determine the effect of a CBD dominant medicinal cannabis on symptoms associated with Long COVID.

First Posted: August 9, 2021

Condition(s): Long COVID

Intervention(s): MediCabilis Cannabis sativa 50

Status: Recruiting

Enrollment (expected or actual): 30

Allocation: N/A

Sponsor: Bod Australia

Principal Investigator:

Completion Date (primary or actual): April 2023

CT.gov Identifier: NCT04997395

This clinical trial is being done to better understand how daily treatment with Tetrahydrocannabinol (THC), Cannabidiol (CBD), or the combination of CBD plus THC affects knee osteoarthritis pain and other related symptoms. Consented participants will have a screening period and visit (up to 30 days to treatment start). If participants pass the screening phase, they will be randomly assigned to take one of the investigational study drugs. For this study, participants will not know when or if they are taking CBD, THC, THC plus CBD, and when or if taking placebo. Clinical pain will be assessed at multiple times throughout the study, and eligibility will be re-assessed at two weeks into the treatment period. It is possible that subjects will not be able to participate in the study after 14 days of of treatment. The treatment period will take approximately 16 weeks and then a follow-up period for approximately 2 weeks. In addition to treatment, participants will have clinical assessments, blood draws, questionnaires, daily pain diaries, sensory testing, as well as have functional connectivity magnetic resonance imaging (fcMRI).

First Posted: August 5, 2021

Condition(s): Osteoarthritis, Knee, Osteoarthritis of the Knee

Intervention(s): Placebo, Cannabidiol (CBD), Tetrahydrocannabinol (Marinol® or generic equivalent (e.g., dronabinol)

Status: Recruiting

Enrollment (expected or actual): 200

Allocation: Randomized

Sponsor: Richard Harris

Principal Investigator: Richard Harris, Associate Professor of Anesthesiology and Associate Professor of Internal Medicine

Completion Date (primary or actual): June 30, 2025

CT.gov Identifier: NCT04992624

To evaluate the effect of the cannabidiol (CBD) + cannabigerol (CBG) + tetrahydrocannabinol (THC) up to 133/66/4mg daily versus placebo as adjuvant treatment in chronic migraine (CM) patients under preventive treatment at a stable dose for at least 3 months who present at least 5 headaches day a month. CM patients of both sexes, between 25 and 65 years old, who have not had CBD and/or THC as a migraine treatment. Patients may be having migraine preventive treatment such as propranolol, topiramate, valproic acid/sodium valproate, flunarizine, amitriptyline, nortriptyline, candesartan, galcanezumab, erenumab, fremanezumab, botulinum toxin type A. Acute treatment will follow patients doctor's prescription. Exclusion criteria: active liver disease or elevated liver transaminases> 3 times than the normal values, pregnancy, fertile age women without contraceptive treatment or who intend to get pregnant, patients without migraine preventive treatment, substance abuse or addiction, use of medical cannabis or products with CBD or THC in the last 30 days or during study period, history of allergy or adverse reactions with the use of CBD or related products, substance users of liver enzymes inducers such as rifampicin, ketoconazole, theophylline, carbamazepine, phenytoin, phenobarbital and St. John's wort. Patients on vitamin K anticoagulant medicines, as warfarin. After randomization patients will be divided into two groups of 55 participants, who will receive CBD + CBG + THC up to a maximum dose of 133/66/4 mg or placebo for 12 weeks (V0 screening, V1 allocation, V4 final visit). The main outcome is the reduction in frequency of headache days per 4 weeks between V1 and V4 compared to placebo. Secondary outcomes will be a reduction in duration and intensity of migraine attacks, amount of painkillers used and percentage of patients with a reduction greater than 50% on migraine days, 50% reduction in the other variables as MIDAS scores, HIT-6 scores, Beck's Anxiety and Depression Scales, Epworth Sleepiness Scales, and the scores at The Severity of Dependence Scale used as an indicator of overuse medication in this sample. The clinical and laboratory data obtained in this study will comply with the objectives elaborated in the evaluation of the primary and secondary, the proposal of which is to publish the data regardless of the results obtained.

First Posted: August 4, 2021

Condition(s): Chronic Migraine, Headache, Overuse Headache Medication

Intervention(s): Placebo oral drops, Cannabidiol + Cannabigerol + Tetrahydrocannabinol 133/66/4mg

Status: Not yet recruiting

Enrollment (expected or actual): 110

Allocation: Randomized

Sponsor: Hospital Israelita Albert Einstein

Principal Investigator: Alexandre Kaup, Principal Investigator, MD

Completion Date (primary or actual): July 18, 2022

CT.gov Identifier: NCT04989413

The study examined a community based cannabis cessation program in Norway (CCP). The CCP uses a combination of cognitive therapy and psychoeducation and covers the normal withdrawal period for cannabis smoking cessation (up to 8 weeks), comprising ~15 individual sessions. From 2005 onwards, the CCP was implemented as a low-threshold community-based program in several Norwegian municipalities, e.g., Kristiansand, Fredrikstad and Oslo. The study had an observational one-group pre- / post test design. Outcomes was changes in cannabis use, mental distress, well-being, social network and sense of coherence (SoC) measured post-intervention (T2) and at a 3 months follow-up (T3).

First Posted: August 4, 2021

Condition(s): Cannabis Use

Intervention(s): Cannabis cessation Program

Status: Completed

Enrollment (expected or actual): 102

Allocation:

Sponsor: Sorlandet Hospital HF

Principal Investigator:

Completion Date (primary or actual): January 31, 2017

CT.gov Identifier: NCT04989205

The American Academy of Pain Medicine has labeled pain as a "silent epidemic" due to its staggering costs to society (over $500 billion/year) and widespread prevalence (affects over 100 million Americans)(Institute of Medicine (US) Committee on Advancing Pain Research, 2011; Summers B, 2005). Thus, it is imperative to test and validate cost-effective pain therapies. To this extent, cannabis is characterized as one of the most promising therapies to treat a wide spectrum of pain conditions (Andreae et al., 2015; Baker, Pryce, Giovannoni, & Thompson, 2003; Bostwick, 2014; Haroutounian et al., 2016; Shohet, Khlebtovsky, Roizen, Roditi, & Djaldetti, 2017). However, the clinical applicability of cannabis-based pain therapies has been limited due to lacking mechanistic characterization in human-focused studies. Of critical importance, the neural mechanisms supporting cannabis induced pain relief remain unknown. The primary objective of the proposed pilot study is to identify the brain mechanisms supporting the direct alleviation of acutely evoked pain through vaporized cannabis.

First Posted: July 29, 2021

Condition(s): Healthy and Chronic Pain Patients

Intervention(s): Active Cannabis, Placebo Cannabis

Status: Not yet recruiting

Enrollment (expected or actual): 100

Allocation: Randomized

Sponsor: University of California, San Diego

Principal Investigator: Fadel Zeidan, Associate Professor of Anesthesiology

Completion Date (primary or actual): August 2024

CT.gov Identifier: NCT04982965

The primary objective of the proposed study is to evaluate the safety and efficacy of Epidiolex (cannabidiol) in adults with obsessive compulsive and related disorders (OCRDs). Subjects will be treated in an open-label fashion with Epidiolex for two weeks.

First Posted: July 27, 2021

Condition(s): Obsessive-Compulsive Disorder, Trichotillomania (Hair-Pulling Disorder), Tourette Syndrome, Hoarding Disorder

Intervention(s): Cannabidiol

Status: Recruiting

Enrollment (expected or actual): 15

Allocation: N/A

Sponsor: University of Chicago

Principal Investigator:

Completion Date (primary or actual): September 2023

CT.gov Identifier: NCT04978428

This is a non-randomised, single arm, open-label study of medical cannabis, Cybis™ 10:25, in participants with chronic back or neck pain in which participants receive escalating doses of Cybis™ 10:25.

First Posted: July 26, 2021

Condition(s): Chronic Pain, Neck Pain, Back Pain, Pain, Pain, Chronic, Pain, Back, Pain, Neck, CBD, THC

Intervention(s): Cybis™ 10:25 THC:CBD oil

Status: Completed

Enrollment (expected or actual): 28

Allocation: N/A

Sponsor: Cymra Life Sciences

Principal Investigator:

Completion Date (primary or actual): June 15, 2022

CT.gov Identifier: NCT04976738

The purpose of this study is to determine the impact of cannabidiol on reward- and stress-related neurocognitive processes among individuals with opioid use disorder on buprenorphine or methadone treatment.

First Posted: July 29, 2021

Condition(s): Opioid-use Disorder

Intervention(s): Cannabidiol 100 MG/ML [Epidiolex], Placebo

Status: Recruiting

Enrollment (expected or actual): 10

Allocation: Randomized

Sponsor: Brigham and Women's Hospital

Principal Investigator: Joji Suzuki, MD, Director, Division of Addiction Psychiatry

Completion Date (primary or actual): August 30, 2022

CT.gov Identifier: NCT04982029

Osteoarthritis (OA), the most common form of arthritis, is a leading cause of disability, affecting the quality of life, pain, and physical functioning of 4.6 million Canadians. About half of OA patients have limited response to primary therapy. The number of OA patients continues to rise, affecting the quality of life of those with OA. There is a dire need to develop future effective treatment options. Cannabis is a potential therapy for those with OA and may provide analgesic, anti-inflammatory, and disease modifying effects. The common barriers to use are a lack of knowledge regarding efficacy, access, and commonly used products, doses and routes of administration. No high-quality clinical trials of cannabis for OA have been conducted, leaving physicians struggling to guide and inform patients regarding symptom relief. Findings from clinical trials of cannabis for other painful conditions have been variable, perhaps due to suboptimal cannabis products and failure to consider important patient characteristics. The goal of the current study is to characterize patient- and cannabis-level factors that are associated with OA pain and address other knowledge gaps.

First Posted: July 21, 2021

Condition(s): Osteo Arthritis Knee

Intervention(s):

Status: Recruiting

Enrollment (expected or actual): 1200

Allocation:

Sponsor: University Health Network, Toronto

Principal Investigator: Hance Clarke, Director Pain Services, Toronto General Hospital

Completion Date (primary or actual): December 2024

CT.gov Identifier: NCT04971629

Cannabis users who experienced a psychosis are particularly vulnerable to cannabis-related harms, which can include worse psychotic symptoms and more hospitalizations. Unfortunately, few psychosocial interventions exist that aim to decrease these harms. Instead, most focus on ceasing cannabis use which is rarely appealing to cannabis users. Furthermore, face-to-face psychotherapy often remains inaccessible to people with psychosis mostly due to lack of trained clinicians. Alternatives such as e-interventions have the potential to increase access to treatment and decrease clinicians' workload. Among cannabis harm reduction approaches are the protective behavioural strategies. These strategies do not encourage nor discourage cannabis use. Instead, they recommend behaviours for safer cannabis use. For example, these strategies include: 1) avoid driving a car under the influence of cannabis, 2) avoid mixing cannabis with other drugs and 3) purchase cannabis only from a trusted source. In the present pan-Canadian study, we will test the first e-intervention called CHAMPS (Cannabis Harm-reducing App for Managing Practices Safely) for cannabis harm reduction adapted for young adult cannabis users who experienced a psychosis. CHAMPS is a smartphone application that includes 17 strategies for safer cannabis use, a personalized consumption goal and a consumption journal. The goals of this study are 1) to confirm whether CHAMPS is acceptable to participants and 2) to test whether it works, notably by positively impacting participants' health and cannabis consumption habits.

First Posted: July 20, 2021

Condition(s): Psychotic Disorder, Marijuana Use, Young Adult

Intervention(s): CHAMPS

Status: Enrolling by invitation

Enrollment (expected or actual): 100

Allocation: Randomized

Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)

Principal Investigator:

Completion Date (primary or actual): September 30, 2023

CT.gov Identifier: NCT04968275

The goal of the current study is to evaluate the bioavaibiltiy of CBD in normal healthy Individuals. This is an open cross-over design study in healthy individuals to assess the safety and pharmacokinetic (PK) effects of cannabidiol.

First Posted: August 26, 2021

Condition(s): Healthy

Intervention(s): Cannabidiol, Cannabidiol, Cannabidiol, Cannabidiol

Status: Recruiting

Enrollment (expected or actual): 24

Allocation: Non-Randomized

Sponsor: Hurd,Yasmin, Ph.D.

Principal Investigator:

Completion Date (primary or actual): August 30, 2022

CT.gov Identifier: NCT05023070

Cannabis is a frequently-used psychoactive substance. While the majority of individuals can use cannabis without experiencing problems, a small minority of people develop cannabis problems. Despite the small-to-medium reported effect sizes of cognitive behavioural therapy (CBT) and motivational enhancement therapy (MET) treatments for cannabis misuse, many cannabis users do not seek treatment. Online CBT/MET programs have the potential to be cost-effective and accessible, and offer a less stigmatizing option for treatment. These programs may also help capture cannabis users who experience subclinical problems, who are not captured by traditional treatment. Existing treatment programs also need to be adapted to maximize participant retention and increase treatment completion, as many current cannabis use treatment programs have significant drop-out rates. Hence, the goal of the proposed randomized controlled trial (RCT) is to examine the efficacy of an online evidence-based CBT/MET treatment program. Outcomes of a combined CBT/MET treatment program will be compared to a CBT-only treatment program and a waitlist control. This research will provide insight into the novel contribution of MET to online CBT treatment programs for cannabis misuse. The researchers are hoping to recruit 303 participants for this study from Central and Eastern Canada. Participants will be randomly assigned to one of the treatment groups (i.e., CBT with MET, CBT without MET) or the psychoeducational control group. Individuals in either treatment group will be given 6 weeks to work through 8 online modules. Throughout the modules, participants will identify goals related to cannabis use, learn strategies to cope with cannabis cravings, triggers, and social pressures and learn to prevent relapse. Participants randomly assigned to the control (i.e., psychoeducation) will receive links to websites that provide general psychoeducation about cannabis use and wellbeing. All participants will complete online assessment measures at baseline, end of treatment, and at follow up approximately one month later (i.e., 0 weeks, 6 weeks, 10 weeks) in order to assess the efficacy of the treatment. At the end of the study, individuals in the control group will be given access to the CBT without MET treatment.

First Posted: July 16, 2021

Condition(s): Marijuana Use, Marijuana Dependence

Intervention(s): Online CBT with MET treatment, CBT without MET treatment

Status: Recruiting

Enrollment (expected or actual): 303

Allocation: Randomized

Sponsor: York University

Principal Investigator: Matthew Keough, Assistant Professor

Completion Date (primary or actual): March 2023

CT.gov Identifier: NCT04965012

The cannabinoid has benefits in many aspects but the evidence of the effect of cannabinoids in humans with SSc is limited. We, therefore, would like to investigate the efficacy of cannabinoids on the appetite, sleep efficiency, quality of life, pain, and critical cytokine level in SSc compared with placebo in SSc patients and the adverse events associated with cannabinoids in those patients.

First Posted: June 13, 2022

Condition(s): Systemic Sclerosis, Malnutrition, Loss of Appetite

Intervention(s): CBD oil, Placebo

Status: Not yet recruiting

Enrollment (expected or actual): 40

Allocation: Randomized

Sponsor: Khon Kaen University

Principal Investigator: Chingching Foocharoen, Professor

Completion Date (primary or actual): December 2023

CT.gov Identifier: NCT05416697

Recent data suggest that the cannabinoid-system is involved in stress regulation and posttraumatic stress disorder (PTSD). Low endocannabinoid signaling has been found in PTSD patients and might even present a precondition to develop PTSD after trauma. The aim of the current project is to investigate the impact of an activation of the cannabinoid system with an exogenous cannabinoid (dronabinol, i.e., delta-9-tetrahydrocannabinol) on fear conditioning.

First Posted: February 7, 2022

Condition(s): Post Traumatic Stress Disorder

Intervention(s): Dronabinol 5 mg, Placebo

Status: Recruiting

Enrollment (expected or actual): 180

Allocation: Randomized

Sponsor: Charite University, Berlin, Germany

Principal Investigator: Stefan Roepke, Prof. Dr. Stefan Röpke

Completion Date (primary or actual): July 2023

CT.gov Identifier: NCT05226351

Evaluate the safety and tolerability of 3-day repeat-dose of SP-104 compared to naltrexone hydrochloride immediate release.

First Posted: July 12, 2021

Condition(s): Healthy Volunteers

Intervention(s): SP-104, Naltrexone immediate release oral capsules

Status: Completed

Enrollment (expected or actual): 52

Allocation: Randomized

Sponsor: Scilex Pharmaceuticals, Inc.

Principal Investigator:

Completion Date (primary or actual): December 20, 2021

CT.gov Identifier: NCT04958876

Subjects will participate in a 4-visit study protocol at the National Advanced Driving Simulator, part of the University of Iowa, in which they will be asked to complete assorted questionnaires, computerized cognitive tasks, and a simulator drive. Subjects will be administered 0.75 mg alprazolam (Xanax) or placebo and 500 mg vaporized cannabis (6.18% THC / <0.025% CBD) or placebo (0% THC / 0% CBD). The primary objective of this study is to validate the Drug Impaired Driving Scenario (DIDS) using the CRCDS-2 driving simulator by assessing the acute effects of cannabis relative to placebo on simulated driving performance. Assay sensitivity will be demonstrated by the significant effect of 0.75 mg alprazolam (active comparator) on driving and cognitive endpoints.

First Posted: July 21, 2021

Condition(s): Driving Behavior, Driving Under the Influence

Intervention(s): Placebo (Lactose) Capsule, 0.75 mg Alprazolam Capsule, Cannabis (6.18% THC / <0.025% CBD), Cannabis (0%/ THC / 0% CBD)

Status: Completed

Enrollment (expected or actual): 13

Allocation: Randomized

Sponsor: Timothy L. Brown

Principal Investigator: Timothy L. Brown, Director of Drugged Driving Research

Completion Date (primary or actual): August 21, 2021

CT.gov Identifier: NCT04970342

A cross-sectional and retrospective chart review study was conducted at the Princess Mother National Institute on Drug Abuse Treatment (PMNIDAT), Thailand. All patients who admitted at PMNIDAT from October 2013 to September 2019 were included. Patients aged 18-65 years who met the International Classification of Disease-10 (ICD-10) criteria of CIP and Had a positive urine test of cannabis were included. Cannabis use is a component cause of psychosis.More than half of symptoms of cannabis-induced psychosis (CIP) were hallucination, delusion, irritable and anxiety. Antipsychotic drug was still a key psychotropic drugs for treatment of CIP. However, antidepressants and benzodiazepines were commonly used for treatment of other symptoms beyond psychotics

First Posted: June 30, 2021

Condition(s): Cannabis

Intervention(s): cannabis

Status: Completed

Enrollment (expected or actual): 317

Allocation:

Sponsor: Mahidol University

Principal Investigator:

Completion Date (primary or actual): May 31, 2020

CT.gov Identifier: NCT04945031